Brief: Cingulate Completes Phase 3 Adult Trial Of CTx-1301 (dexmethylphenidate) For ADHD
08/06/2023 12:29
June 8 (Reuters) - Cingulate Inc CING.O :
* CINGULATE COMPLETES PHASE 3 ADULT TRIAL OF CTX-1301
(DEXMETHYLPHENIDATE) FOR ADHD
* CINGULATE INC - PIVOTAL PHASE 3 TRIALS IN
PEDIATRIC/ADOLESCENT
PATIENTS ON SCHEDULE FOR 3Q 2023 INITIATION
* CINGULATE INC - PLANS TO SUBMIT A NEW DRUG APPLICATION FOR
CTX-1301 IN MID-2024 UNDER SECTION 505(B)(2) PATHWAY
Source text for Eikon: ID:nGNX5Cwrkc
Further company coverage: CING.O
Recent news on Cingulate
See all newsBrief: Cingulate Announces Publication Of Phase 3 Adhd Trial Results In Journal Of Child And Adolescent Psychopharmacology
NASDAQ RESUMED AT 09:39 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
NASDAQ RESUMED AT 08:30 AM
FDA declines to approve Cingulate's ADHD treatment over manufacturing issues (updated)